D.A. Davidson & Co’s PDL BioPharma, Inc. PDLI Stock Holding History

D.A. Davidson & Co’s Portfolio PDLI Stock Details PDLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-38,900	Closed	-$137K	–	2439
2015 Q4	$137K	Sell	38,900 -1,367	-3%	-$5.72K	﹤0.01%	996
2015 Q3	$202K	Sell	40,267 -941	-2%	-$5.39K	0.01%	815
2015 Q2	$264K	Sell	41,208 -1,755	-4%	-$11.8K	0.01%	764
2015 Q1	$302K	Sell	42,963 -1,931	-4%	-$14K	0.01%	726
2014 Q4	$346K	Sell	44,894 -3,855	-8%	-$30.5K	0.01%	687
2014 Q3	$364K	Buy	+48,749	New	+$453K	0.01%	674
2014 Q2	–	Sell	-4,120	Closed	-$34K	–	2260
2014 Q1	$34K	Hold	4,120	–	–	﹤0.01%	1522
2013 Q4	$34K	Buy	+4,120	New	+$34.7K	﹤0.01%	1433

Other funds holding PDLI

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

GAM

Gotham Asset Management New York $32.7B AUM 27.65% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

D.A. Davidson & Co's PDLI Position: Q1 2016 in Review

D.A. Davidson & Co sold out of PDL BioPharma, Inc. (PDLI) in Q1 2016, closing a stake of 38,900 shares — an estimated $137K sold.

D.A. Davidson & Co first reported a position in PDLI in Q4 2013 and held it in 8 quarters. The position peaked at $364K in Q3 2014. 195 funds tracked by Wall St. Rank hold PDLI as of Q1 2016.

D.A. Davidson & Co reported no remaining PDL BioPharma, Inc. position as of Q1 2016 after selling out during the quarter.
D.A. Davidson & Co sold 38,900 PDL BioPharma, Inc. shares in Q1 2016, an estimated $137K.
D.A. Davidson & Co first reported a position in PDL BioPharma, Inc. in Q4 2013 and held it in 8 quarters.
D.A. Davidson & Co's PDL BioPharma, Inc. position peaked at $364K in Q3 2014.
195 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q1 2016.

Based on D.A. Davidson & Co's 13F filing for Q1 2016, filed 13 May 2016.